A preclinical biotechnology company, spun out of The University of Manchester, has completed a £62m (€72m) finance deal to develop the treatment of a leading cause of blindness. The Germany-based company, Complement Therapeutics GmbH (CTx), specialises in disorders that affect the part of the body’s immune system called the Complement cascade. CTx was spun out … Continue reading University BioTech spinout completes £62m finance deal